Abstract
For decades, ibogaine – the main psychoactive alkaloid found in Tabernanthe iboga – has been investigated as a possible treatment for substance use disorders (SUDs) due to its purported ability to interrupt the addictive properties of multiple drugs of abuse. Of the numerous pharmacological actions of ibogaine and its derivatives, the inhibition of α3β4 nicotinic acetylcholine receptors (nAChRs) represents a probable mechanism of action for their apparent anti-addictive activity. In this Perspective, we examine several classes of compounds that have been discovered and developed to target α3β4 nAChRs. Specifically, by focusing on compounds that have proven efficacious in pre-clinical models of drug abuse and have been evaluated clinically, we highlight the promising potential of the α3β4 nAChRs as viable targets to treat a wide array of SUDs. Additionally, we discuss the challenges faced by the existing classes of α3β4 nAChR ligands that must be overcome to develop them into therapeutic treatments.
Keywords: Nicotinic acetylcholine receptors, substance use disorders, ibogaine, 18-MC, mecamylamine, AT-1001, α-conotoxins
Graphical Abstract

INTRODUCTION
Due to its potent hallucinogenic properties, root bark from the central African iboga shrub (Tabernanthe iboga) has been harvested and ingested for centuries by Bwiti and Mbiri practitioners during rituals.1,2 Over the last several decades, the use of T. iboga or ibogaine, the major psychoactive iboga alkaloid, has attracted growing interest in other parts of the world due to their purported abilities to cure drug addictions (Figure 1). These claims were first tested clinically in 1955 when the National Institute of Mental Health Addiction Research Center administered ibogaine to prisoners with prior histories of opioid dependence.3 As with many hallucinogens, ibogaine was quickly diverted to recreational use in the United States. One user in particular, Howard Lotsof, became convinced of its anti-addictive properties after having a transformational experience with the drug in the early 1960s,4 leading him to champion efforts to investigate ibogaine’s use as a treatment for substance use disorders (SUDs). In five United States patents issued to Lotsof between 1985 and 1992, he claimed the use of ibogaine to have long-lasting efficacy in the treatment of opiate, cocaine, amphetamine, alcohol, and nicotine dependence.5-9 Although these claims remain to be validated through rigorous, double-blinded clinical trials, the medical subculture surrounding Howard Lotsof and iboga introduced ibogaine to mainstream academic circles. With the recent resurgence in interest in psychedelics as legitimate pharmacotherapies, the history of ibogaine feels acutely relevant.
Figure 1.

Structures of iboga alkaloids and their analogs.
Stanley Glick, a physician-scientist at Albany Medical College, was initially skeptical of Lotsof’s claims of ibogaine’s efficacy. However, after hearing similar accounts from numerous other ibogaine users, Glick came to “believe that there [was] at least something there that [was] worth investigating” and began testing ibogaine in rodent models of substance abuse.10 The results from these studies generally corroborated Lotsof’s claims: in rats, ibogaine decreased intravenous morphine and cocaine self-administration, as well as oral intake of alcohol and nicotine.11-13 Despite these encouraging in vivo effects, the therapeutic potential of ibogaine is limited by its potentially life-threatening side effects.14 Ibogaine and its major metabolite noribogaine (Figure 1) inhibit hERG channels, resulting in QT interval prolongation that can persist for over a week and progress to acute heart failure or cardiopulmonary arrest.14 Ibogaine is also an oneirogen—an agent that produces or enhances dreamlike states of consciousness—and is infamous for inducing intensely unpleasant psychological effects.4 Consistent with the side effects reported by human users, ibogaine also induces cardiotoxicity, neurotoxicity, and whole-body shaking in rats.14-18
In hopes of discovering a compound with similar potential to treat SUDs and an improved side effect profile, Glick and synthetic chemist Martin Kuehne began developing analogs of ibogaine.19 Their initial work revealed that the structurally related iboga alkaloids ibogamine and coronaridine mimicked ibogaine’s effects on morphine and cocaine self-administration.16,20 However, unlike ibogaine, coronaridine did not cause tremors in rodents, making it an attractive starting compound for derivatization.16 Coronaridine’s synthetic analogue 18-methoxycoronaridine (18-MC) decreased morphine and cocaine self-administration in rats without inducing tremoring or neurotoxicity, demonstrating that it was possible to dissociate the anti-addictive efficacy from ibogaine’s characteristic side effects.16 It was later discovered that 18-MC inhibits nicotinic acetylcholine receptors (nAChRs), with a modest selectivity for α3β4 over other neuronal nAChR subtypes, providing the first mechanistic hypothesis for the anti-addictive properties of ibogaine and its derivatives.21-24
The nAChRs are a family of ligand-gated ion channels found throughout the peripheral and central nervous systems (CNS). Humans express 11 different nAChR subunits in the CNS – eight α-subunits (α2-7, α9, and α10) and three β-subunits (β2-β4). Each subunit is composed of four transmembrane domains with extracellular amino- and carboxy-termini. These subunits assemble into a large assortment of homo- or hetero-pentamers known as subtypes. nAChR subtypes differ in their location of expression, biophysical properties (i.e., channel open time, desensitization rate, and ion selectivity), and sensitivity to agonists and antagonists.25-28 Based on these differences, specific nAChR subtypes have been implicated in a variety of CNS diseases and disorders including epilepsy (α4β2)29 Alzheimer’s disease (α4β2, α7),30 Parkinson’s disease (α6β2, α4β2),31 inflammation (α9α10, α7),32 schizophrenia (α7),33 neuropathic pain (α9α10, α6β4),34 and drug addiction (α3β4, α4β2, α6β2).35,36 Because it is the most abundant nAChR subtype in the CNS, medicinal chemistry efforts have largely focused on the α4β2 subtype, ultimately leading to the development of the α4β2 partial agonist varenicline as a smoking cessation aid.
As the name suggests, nAChRs are activated by the endogenous neurotransmitter acetylcholine and the exogenous agonist nicotine. The orthosteric sites are situated at the two α(+)/β(–) interfaces (Figure 2) and characterized by an “aromatic box” consisting of a series of tryptophan and tyrosine residues arranged to simultaneously form cation-π interactions with the cations found in many nAChR orthosteric ligands.38 In addition to this highly conserved motif, the nAChR orthosteric site is defined by the α subunits’ loop C, which contains a characteristic disulfide bridge formed between two adjacent cysteine residues. Evidence from acetylcholine binding proteins (AChBPs), soluble homologs of the extracellular domains of nAChRs found in certain mollusks, indicates that agonist or antagonist binding in the orthosteric site induces a conformational change in the receptor with loop C moving towards or away from the ligand, respectively.39 This movement in loop C is believed to be correlated with the opening of the ion channel.40
Figure 2.

Overview of ligand binding to α3β4 nAChRs.
= channel-blocking site (mecamylamine),
= orthosteric site (α-conotoxins, AT-1001, PF-4575180, CP-601932),
= proposed allosteric site (18-MC); open shapes = supported by docking studies only, solid shapes = supported by both docking and experimental studies. The + and – on the subunits refer to the principle and complementary faces of the binding sites, respectively. Receptor image created from cryo-EM structure of α3β4 nAChR (PDB: 6PV8) bound to AT-1001 (red spheres).37
In contrast to the rest of the CNS where the α4β2 and α7 subtypes predominate, the medial habenula (MHb) and interpeduncular nucleus (IPN) contain a localized density of the α3β4 subtype.41 Projections from the MHb innervate the IPN, which connects to the ventral tegmental area (VTA), a classical “reward center” of the brain composed largely of dopaminergic (DA) neurons.42,43 Cholinergic signaling along this MHb-IPN pathway, modulated by the α3β4 nAChR, activates DA neurons in the VTA to release dopamine, which contributes to the rewarding effects of drugs of abuse.44 Most drugs of abuse have downstream mechanisms that relay input to the neurons in the VTA, making the α3β4 nAChR critical to the development of substance use disorder treatment. In further support of the α3β4 nAChRs’ modulating the addictive properties of drugs of abuse, polymorphisms in genes encoding the α3β4 nAChR have been associated with increased risk for tobacco and alcohol abuse and increased dependence liability.45 Taken together, the anatomical and genetic data provide strong evidence that the α3β4 nAChRs in the MHb-IPN axis play an important role in addiction and that inhibiting these receptors could be an effective strategy for treating SUDs.
In the decades since the initial discovery of its potential anti-addictive properties, ibogaine has inspired numerous avenues of research to develop a treatment for SUDs. Included among these efforts is the very recent discovery of ibogaine derivatives with minimal α3β4 nAChR affinity, which have instead been developed as non-hallucinogenic 5-HT2A agonists or novel agonists of the κ opioid receptor.46,47 Similarly, the discovery of a putative receptor target for ibogaine and its derivatives has spurred research to investigate the role played by the α3β4 nAChRs in SUDs and the development of new classes of ligands to target them. While several reviews have provided detailed summaries of a single compound class, such as the iboga alkaloids, they have lacked a comprehensive overview of the α3β4 subtype and its potential as a target for SUD pharmacotherapies.19,48 Within this perspective, we examine the α3β4 nAChR through the lens of the different ligand classes that have shown efficacy in preclinical and clinical studies of SUDs. Additionally, we will discuss the remaining challenges and new opportunities to translate these compounds into effective treatments for SUDs.
18-MC
Although ibogaine possesses adverse effects that limit its therapeutic utility, its efficacy in animal models of SUDS and its novel mechanism of action led Glick and Kuehne to investigate derivatives of ibogaine in hopes of identifying a compound that lacked cardiotoxicity and negative behavioral effects.19 Voacangine and coronaridine, which bear additional methyl esters at the C16 position of ibogaine (Figure 1), were identified as promising starting points because they lack tremorgenic activity.49 To investigate these possibilities, a series of ibogaine derivatives were synthesized using the route originally developed by Kuehne for the synthesis of coronaridine (Scheme 1). Condensation of aldehyde 1 with the N-benzylated indoloazepine (2) and subsequent fragmentation and intramolecular Diels-Alder afforded a tetracyclic intermediate 3.49 Cleavage of the C3-C7 bond, debenzylation by hydrogenolysis, hydrolysis of the acetal function, and spontaneous cyclization provided enamine 4. Heating 4 in toluene induced a C16 to C20 proton transfer and cyclization to form the isoquinuclidine core.49 Notably, this synthetic sequence provides straightforward access to the ibogaine core, albeit in racemic fashion. Individual enantiomers have been isolated through the introduction of chiral auxiliaries in the synthetic sequence.50 Furthermore, this route was adapted to include additional substitutions at C18 allowing for the synthesis of albifloranine (18-hydroxycoronaridine), an alkaloid originally isolated from the Tabernaemontana albiflora, and its derivative 18-methoxycoronaridine (18-MC). Evaluation of these synthetic ibogaine derivatives ultimately revealed that 18-MC is effective in rodent models of inhibiting morphine and cocaine administration while improving the side effect profile.16
Scheme 1.
Synthesis of ibogaine derivative (±)-18-MC.
18-MC lacks the tremors and neurotoxicity associated with ibogaine.17 Whereas ibogaine induces whole-body tremors at doses as low as 20 mg/kg, rats treated with a high dose of 18-MC (100 mg/kg) displayed no apparent tremoring.16,51,52 Histologically-prepared brains of rats that received up to three 100 mg/kg doses of 18-MC were identical to naïve or saline-dosed rats, suggesting that 18-MC does not cause Purkinje cell degeneration, a hallmark of neurotoxicity.53 This difference in side effect profile between 18-MC and ibogaine is generally attributed to the latter’s promiscuous binding to multiple CNS receptors. Ibogaine and its active metabolite noribogaine (Figure 1) have low micromolar affinities for several CNS receptors, including nAChRs, opioid receptors, NMDA receptors, σ2 receptors, muscarinic (M1 and M2) receptors, 5-HT3 receptors, sodium channels, σ2 sites, and the serotonin transporter (Table 1). In support of this notion that polypharmacology produces side effects, 18-MC binds more selectively to the α3β4 nAChRs than ibogaine.21 Nevertheless, a receptor screen conducted via radioligand binding assays revealed that 18-MC retains significant affinity for many of these targets (Table 1).19 Increased target selectivity is likely necessary to lessen the remaining side effects of motor function depression and sedation exhibited in rodent models of 18-MC.16,54
Table 1.
Compound summary (* denotes calcium flux assay, ^ denotes electrophysiology assay, # denotes radioligand binding competition experiment)
| Class | Compound | α3β4 | Other nAChRs | Other Receptors | References | |
|---|---|---|---|---|---|---|
| Ki (nM) | IC50 (μM) | Ki (nM)/ IC50 (μM) | Ki/IC50 (μM) | |||
| Iboga alkaloids | ibogaine | 1.05 ± 0.12# | 0.95 ± 0.13*, 0.22^ | α4β2 (IC50): 1-5^ | Ki: KOR: 2.2 ± 0.10#; MOR: 2.0 ± 0.15#; DOR: >10#; 5-HT3: 2.6 ± 0.23#; M1: 16 ± 1.0#; σ2: 0.4 ± 0.036#; sodium channel: 3.6 ± 0.35#; NMDA: 3.1 ± 0.30#; 5HT-uptake: 4.1 ± 0.83# IC50: 4.09 ± 0.69 (hERG)^ |
2,21,56,162 |
| (±)-18-MC | 400 ± 140# 700^ |
1.47 ± 0.21* 0.75^ |
α4β2 (IC50): 6.3 ± 1.3, >20^; α7 (IC50): 34.7 ± 5.0* | Ki: KOR: 5.1 ± 0.50#; MOR: 1.1 ± 0.30#; DOR: 3.5 ± 0.05#; 5-HT3: 3.8 ± 0.067#; M1: 32 ± 3#; σ2; 13 ± 1.2#; sodium channel: 6.4 ± 0.68# IC50: >50 (hERG)^ |
2,19,21,57,163-165 | |
| Channel blocker | (±)-mecamylamine | 600 | 1.1 ± 0.1^ | α4β2 (Ki): 2500; α7 (Ki): 6900 | 68,75,157 | |
| α-conotoxins | AuIB | 0.770^ | α3β2 (IC50): >100^; α7 (IC50): >100^; α4β2 (IC50): >100^ | 117,118 | ||
| TxID | 0.0125^ | α6/α3β4 (IC50): 0.094^; α2β4 (IC50): 4.55^; α4β2 (IC50): >100^ | 120 | |||
| RegIIA | 0.097^ | α3β2 (IC50): 0.033^; α7 (IC50): 0.103^; α4β2 (IC50): >100^ | 123 | |||
| [S9A]TxID | 0.0039^ | α6/α3β4 (IC50): 0.178 | 130 | |||
| [S9K]TxID | 0.0069^ | α6/α3β4 (IC50): >100 | 131 | |||
| [R10F][N12L]LsIA | 0.41 ± 0.02* | α7 (IC50): >100* | 124 | |||
| TP-2212-59 | 0.0023* | α4β2 (IC50): >100* | 132 | |||
| Azabicyclic partial agonists | AT-1001 | 2.64 ± 0.24* | 0.03 ± 0.01 | α4β2 (Ki): 476.52 ± 98.75/(IC50): 0.30 ± 0.20; α7 (Ki): 221.72 ± 9.88* | IC50: 5-HT3: 0.6; H1: 0.201; M4: 0.661; M5: 0.325; σ2: 0.418; σ1; 0.084 | 145,147 |
| PF-4575180 | 4.2 ± 0.9# | 0.112 ± 25* | α4β2 (Ki): >1195 ± 475#/(IC50): 0.73 ± 0.20* | 153 | ||
| CP-601932 | 21 ± 28# | 0.26 ± 0.04* | α4β2 (Ki): 21 ±19#/ (IC50): 0.11± 0.02* | 155 | ||
Experimental and computational methods have been used to propose a binding site for 18-MC and ibogaine on α3β4 nAChRs. In PC12 cells that express α3β4 nAChRs, the inhibition of channel opening by ibogaine is not overcome by increasing concentrations of nicotine, indicating ibogaine likely does not bind to the orthosteric site.55 Similar non-competitive inhibition has been observed for 18-MC in TE671 cells that express muscle-type nAChRs. In HEK293 cells expressing α3β4 nAChRs, ibogaine and 18-MC inhibit acetylcholine-evoked responses with similar potencies (Table 1), and the concentration-response relationships have a Hill slope near unity, suggesting a single-site of action.21 Data from radioligand binding experiments with [3H]ibogaine further support a single binding site and that ibogaine dissociates faster from the closed state of the receptor compared to the desensitized state.56 Although experimental evidence to discern this binding site is lacking, docking and molecular dynamic simulations have proposed several binding sites within the channel pore for 18-MC and ibogaine.57 These computational methods suggest 18-MC and ibogaine binding are driven through van der Waals interactions with hydrophobic residues and pi-pi stacking interactions with Phe255 of the β4 subunit.57
18-MC has demonstrated efficacy in decreasing self-administration in various rodent models of drug abuse. 18-MC dose-dependently (10-40 mg/kg i.p. and p.o.) decreased morphine self-administration in rats for at least one day and up to three weeks following treatment.16,17 In a strain of selectively bred alcohol-preferring rats, 18-MC (5-40 mg/kg i.p. and p.o.) significantly reduced alcohol drinking in a dose-dependent manner.12,58 In line with these results, 30 mg/kg 18-MC decreased binge-like ethanol consumption in mice as determined in the drinking-in-the-dark paradigm.59
18-MC is similarly effective in preventing stimulant use in rodents. 18-MC (10-40 mg/kg i.p. and 5-40 mg/kg p.o.) significantly reduced nicotine self-administration in rats in a dose-dependent manner.13,58 When administered p.o., this effect persisted for over 24 hours.13 Rats treated with 18-MC (2-40 mg/kg i.p.) substantially decreased nicotine self-administration, even at the lowest dose of test compound.60 Although less effective than with other drugs of abuse, 18-MC also decreases methamphetamine self-administration; 18-MC (40 mg/kg i.v.) reduced methamphetamine self-administration to 40% of baseline.60 Similarly, 18-MC (10-40 mg/kg i.p.) decreased cocaine self-administration in rats, with the highest dose depressing intake up to three weeks.16 The same doses also attenuated cocaine craving in rats, as determined through a cue-induced reinstatement model.61
Several self-administration studies delivering 18-MC to specific brain regions have provided strong evidence that the observed efficacy in these animal models of SUDs stems from α3β4 antagonism. Administering 18-MC directly into either the MHb or the IPN, areas containing high densities of α3β4 nAChRs, decreased morphine and methamphetamine self-administration in rats.62,63 Conversely, administration of 18-MC into the VTA, an area of the brain lacking α3β4 but classically associated with drugs of abuse, had no effect on the self-administration of either drug.62,63 These data are consistent with a mechanism of action mediated by antagonism of α3β4 nAChRs in the MHb-IPN pathway. The nonselective nAChR antagonist mecamylamine and α3β4-selective antagonist α-conotoxin AuIB showed comparable effects when applied locally to these three areas, further suggesting that 18-MC’s anti-addictive properties result from its antagonism of α3β4 nAChRs.62
Although antagonism of the α3β4 nAChR does not fully explain the prolonged anti-addictive effects observed in many of the aforementioned studies, it nonetheless is the prevailing theory to explain the efficacy of 18-MC in animal models of SUDs. 18-MC’s long-lasting effects against multiple drugs of abuse have provided strong support for the α3β4 nAChR as a target for the treatment of SUDs and a considerable improvement over ibogaine with regard to adverse effects, toxicity, and selectivity. Nevertheless, 18-MC is only a modestly potent and selective α3β4 nAChR antagonist. According to Glick et al., 18-MC has >20-fold greater affinity for α3β4 over α4β2;26 however Arias et al., have reported a more modest 4-fold selectivity.64 Furthermore, as discussed above, 18-MC also has considerable affinity for μ, δ, and κ opioid receptors.19 Since opioid receptors have a well-established role in SUDs, 18-MC’s affinities for all three opioid receptors may contribute to its mechanism of action.22,46,65 Despite its moderate α3β4 potency and selectivity, clinical trials have been initiated for 18-MC. In early 2022, the biopharmaceutical company MindMed reported the completion of a Phase 1 clinical trial where 18-MC was shown to be well tolerated at doses up to 500 mg/day in Single Ascending Dose and 60 mg/day in Multiple Ascending Dose. Initially, MindMed had announced plans to begin a Phase 2a proof-of-concept study for the treatment of opioid use disorder based on these encouraging results but has recently shelved the development of 18-MC.66 Nevertheless, these Phase 1 results do indicate that α3β4 nAChRs could be safely inhibited, suggesting more selective α3β4 ligands will also be well tolerated.
MECAMYLAMINE
Mecamylamine (MEC) was initially introduced to the United States by Merck as Inversine® in the 1950s (Figure 3). It was among the first orally active medications available for the management of hypertension.67 Following the development of new classes of antihypertensive drugs with greater efficacy and more favorable side effect profiles, MEC fell out of favor in clinical applications. However, it remains a widely-used research tool for studying the pharmacology of nAChRs.
Figure 3.

Mecamylamine enantiomers.
MEC is a non-competitive and non-selective inhibitor of all known nAChRs subtypes. MEC’s inhibition of the nAChRs is voltage-dependent, a phenomenon that is typically observed with compounds that interact within the voltage field of other ion channels.68 In competitive radioligand binding studies, phencyclidine and verapamil, which bind to pores of NMDA and calcium channels respectively, exhibit affinity for the [3H]-MEC site.69,70 Additionally, [3H]-MEC binding to nAChRs increases in the presence of the channel-opening agonist nicotine. Similarly, the binding of MEC to the channel pore of muscle nAChRs induces a conformational change that prevents the release of MEC that can only be reversed by the reopening of the channel by an agonist.71,72 Taken together, these lines of evidence indicate that MEC is an open channel blocker. That is, it exerts its inhibitory action on the nAChRs by binding to the pore of the open channel, which prevents the flow of ions.73-76
Although Inversine® contains racemic MEC, examination of the pharmacological properties of the individual enantiomers of MEC began shortly after the racemate was developed.77 Though initial research suggested there is no difference in the enantiomers’ affinity or inhibitory potency at nAChRs, later reports have observed some differences.75,78 Specifically, (+)-MEC dissociates more slowly from α4β2 and α3β4 receptors than (–)-MEC.78,79 In vivo, (+)-MEC produces more robust antidepressant and anxiolytic activity.80
In animal models of drug abuse, MEC has proven effective at decreasing drug-seeking behavior for several drugs of abuse. As described above, MEC decreases the self-administration of methamphetamine in rats when directly administered to the MHb or IPN.62 Despite MEC’s activity at all nAChR subtypes, these effects are likely the result of inhibition of α3β4 nAChRs, since this is the predominant subtype in these brain regions.81,82 Numerous studies have also demonstrated that systemic administration of MEC (0.5-3 mg/kg s.c. or 0.3-3 mg/kg i.p.) to rats and mice dose-dependently decreases nicotine self-administration.83-89 These effects were also observed in non-human mammals, where MEC pre-treatment decreased nicotine self-administration in beagles (1 mg/kg i.v.) and squirrel monkeys (1 mg/kg i.m.).83-91 A limited number of studies examining other drugs of abuse have demonstrated similar results. Pretreatment with MEC produces a dose-dependent depression of cocaine self-administration (0.3-3 mg/kg i.p. or 1-4 mg/kg s.c.)86,92 and ethanol drinking (0.5-8 mg/kg i.p. or 0.5-2 mg/kg s.c.)93-97 in rats and mice.
Corroborating the results of animal models, MEC has been examined clinically where it was shown to successfully decrease nicotine and alcohol use. Due to its ability to cross the blood-brain barrier (BBB), MEC inhibits neuronal nAChRs at lower doses (2.5-15 mg/day) than those used to treat hypertension (25-80 mg/day). Initial doses of 5-10 mg/day, increasing over three weeks, were 50% successful in withdrawing treatment-resistant smokers from nicotine.98,99 In another trial, smokers received an intervention of a nicotine skin patch plus MEC (2.5-5 mg BID) or placebo. The continuous abstinence rate was three times higher in the MEC condition, and MEC significantly reduced self-reported cravings for cigarettes.100 Similarly, MEC (7.5-15 mg/day) was self-reported to decrease the rewarding and euphoric effects of alcohol, as well as the desire to consume alcohol.98,99,101-103 However, the higher dosages used in these studies led to constipation, urinary retention, and abdominal cramps.74,104-106
In summary, due to MEC’S inhibitory effect on multiple nAChR subtypes, it may have efficacy in treating several CNS conditions, including SUDs. However, the unfavorable side effects that have caused its use as an antihypertensive agent to diminish will also likely make it an unattractive treatment for SUDs. MEC’s unselective inhibition of all known nAChR subtypes, both neuronal and muscular, and off-target effects cause constipation, urinary retention, abdominal cramps, and dry mouth and skin.106 Nevertheless, it remains an invaluable tool for studying the physiological roles of nAChRs. Moreover, the successful application of MEC in preclinical and clinical investigations has aided in establishing the nAChRs, particularly the α3β4 subtype, as promising targets for the treatment of SUDs.
α-CONOTOXINS
Around 750 species of cone snail from the genus Conus have been identified, all of which hunt their prey using a wide range of specialized peptide-based neuropharmacological venoms.107,108 These small disulfide-constrained peptides, known as conotoxins, are present and conserved in all phylogenetic clades of Conus. Divided into at least 16 genetically distinct superfamilies categorized by their cysteine framework, these peptides are further divided into families by their target, either voltage- or ligand-gated ion channels.107,109 Though fewer than 1% of estimated Conus peptides have been sequenced and investigated, those that have been studied typically display extraordinary target specificity. Researchers have exploited conotoxin’s ability to differentiate between homologous channels to identify and define novel receptors within large ion channel families, including the functions of specific subtypes.107,108,110,111 While it may seem counterintuitive to treat diseases with toxins, the high specificity of the conotoxins has made them ideal pharmacological tools for studying the physiological function of certain ion channels, including the nAChRs.107,110-114
Nearly all nAChR-targeting conotoxins fall into the α-conotoxin family, the largest group of conotoxins characterized thus far.107,109,112 Among the smallest conotoxins, they contain only 12-20 amino acid residues. The α-conotoxins’ cysteine framework consists of four cysteines in a CICII(m)CIII(n)CIV sequence, where m and n refer to amino acid loops of varying size.113,114 The four cysteine residues form two disulfide bonds, resulting in three distinct isomers with significantly different activities. Native α-conotoxins typically adopt the more active globular isomer, with disulfide bonds between CI-CIII and CII-CIV.115,116 Two highly conserved Ser4 and Pro6 residues in the m loop are believed to orient the peptide towards the nAChR orthosteric binding pocket, while a more variable n loop dictates subtype-selectivity.
In 1998, the McIntosh group isolated the first α3β4-selective α-conotoxin, AuIB, from C. aulicus (Figure 4).117,118 In its native globular conformation, AuIB potently antagonizes the α3β4 subtype, while very weakly inhibiting the α7 subtype. At the time, this high subtype-selectivity made it unique among other α-conotoxins identified.116 To understand this subtype-selectivity, Grishin et al. developed a homology model of AuIB bound to the orthosteric site of the α3β4 nAChR based on a crystal structure of a PnIA, a different α-conotoxin, bound to the AChBP from Aplysia californica.119 This model suggested the N-terminus of AuIB forms a salt bridge with the Asp172 of the β4 side chain. Additionally, the Phe9 of AuIB was proposed to interact with a two-residue binding pocket on the β4 nAChR subunit through π-π stacking, indicating it may be responsible for the observed subtype-selectivity. Providing further evidence for this AuIB binding site, mutating Trp59 and Lys61 from the orthosteric site of the β4 subunit abolished AuIB inhibitory activity, suggesting these residues are necessary for its binding. Despite these results suggesting AuIB binds to the orthosteric site, some studies have shown other α-conotoxins produce non-competitive antagonism of nAChRs.120,121
Figure 4.
Amino acid sequence and IC50 values of natural and synthetic α3β4-selective α-conotoxins.
Since the discovery of AuIB, there has been a continued search for other α-conotoxins that inhibit α3β4 with greater potency. In 2013, TxID, isolated from C. textile, was identified as an α3β4 antagonist 60 times more potent than AuIB (Figure 4).120 Because it has the same Ser4 and Pro6 region found in many other α-conotoxin m loops, the observed increase in potency is believed to be due to unique residues in the n loop. TxID also inhibits the related α6/α3β4 nAChR subtype, albeit less potently, and weakly blocks α2β4.109 In addition to TxID, several other α-conotoxins that inhibit α3β4 also target other nAChR subtypes. RegIIA, identified by the Marí group, is an α-conotoxin isolated from C. regius and another potent α3β4 nAChR antagonist.122,123 Although RegIIA also has activity at the α7 and α3β2 subtypes, unlike some other α-conotoxins, RegIIA does not affect GABAB-mediated signaling.114 Other α-conotoxins, including Vc1.1, BuIA, PeIA, PIA, GIC, and LvIA, weakly antagonize α3β4 nAChRs but show more potent activity at other nAChR subtypes.110,124-128
Due to their modular, peptidic nature, several studies have examined how changes to the peptidic sequence of the α-conotoxins impact their potency and selectivity for the α3β4 nAChRs. In its native form, the α-conotoxin LsIA only differs from the majority of α3β4-active α-conotoxins by four residues, yet it is inactive at α3β4.129 Abraham et al. developed analogues of LsIA to further understand the minimum structural requirements for α-conotoxin activity at human α3β4 (Figure 4).124 Guided by homology models generated using a co-crystal structure between LsIA and the Lymnea stagnalis AChBP, substitutions at LsIA Arg10 resulted in a salt bridge and cation-π interactions with Lys57 on the β4 subunit of the α3β4 nAChR, while substitutions at LsIA Asn12 introduced interactions with Ile77 and Ile109 at a hydrophobic patch on β4. Together, these changes resulted in α3β4 nAChR activity. Most notably, the [R10M]LsIA and [N12L]LsIA analogues inhibited the α3β4 nAChR 5- and 40-fold more potently than the α7 nAChR subtype, respectively. These simple modifications to the LsIA sequence suggest that interactions between the α-conotoxins and the Lys61, Ile81, and Ile113 triad on the β4 subunit form the minimum pharmacophore required for α3β4 inhibition. To support this, a [R10F][N12L]LsIA double mutant showed no activity at α7 up to 100 μM and an improved IC50 at α3β4. In a separate study, the Luo group used positional alanine scanning and site-directed mutagenesis to identify five key residues in TxID necessary for both α6/α3β4 and α3β4 inhibition: His5, Pro6, Val7, Met11, and Pro13. Substituting an alanine for Ser9 revealed an [S9A]TxID analogue with 46-fold improved selectivity between α3β4 and α6/α3β4 subtypes (Figure 4).130 Additional single amino acid substitution at that position resulted in an [S9K]TxID analogue with complete selectivity for the α3β4 nAChR.131 Inspired by a different α-conotoxin, the Armishaw group systematically modified key amino acid residues in the m and n loop framework of BuIA, creating a positional scanning library of analogues. This library consisted of 132 mixture samples, each containing 5,153,632 compounds across six sublibraries, for a total of 113,379,904 possible individual amino acid combinations.132 Through two rounds of library generation, they determined which amino acids within the n loop were most involved in α3β4. Of their leads, TP-2212-59 was found to be the most potent antagonist, competitively inhibiting only α3β4 nAChRs (Figure 4). Currently, [S9K]TxID and TP-2212-59 are the most selective and potent α3β4-targeting α-conotoxins reported to date, respectively.
As α-conotoxins are some of the most selective α3β4 nAChR antagonists identified, they have been used extensively to study the role of these receptors in modulating the effects of drugs of abuse. As the first α3β4-targeting α-conotoxin identified, the majority of these studies have employed AuIB. In acute nicotine administration, pre-treatment with AuIB by direct administration into the MHb of rats prevented nicotine-induced increases in extracellular dopamine in the nucleus accumbens.133,134 Additionally, direct infusion to the MHb, BLA, or dorsolateral tegmentum (DLT) (25 pmol i.c.v.) decreased nicotine self-administration.135 AuIB also prevented the expression of nicotine-conditioned place preference (CPP) and decreased nicotine withdrawal symptoms. Like AuIB, pre-treatment with TxID (0.2-5 nmol i.c.v) and its more α3β4-selective analogue, [S9K]TxID (0.2-5 nmol i.c.v.) also significantly attenuated the expression and reinstatement of nicotine CPP in mice, further suggesting the importance of the α3β4 nAChR in the rewarding effects of nicotine.136 However, when AuIB was infused into the IPN of rats, increased levels of self-administered nicotine were observed. Similar results were seen when 18-MC was locally administered into the IPN.135,137 These in vivo studies indicate that α3β4 has multiple roles in both the addictive and adverse properties of nicotine.
α-conotoxins are also gradually being applied to other models of substance abuse. For example, similar infusion studies were done with AuIB in rats to investigate the role of α3β4 in methamphetamine SUD.62 When administered to either the IPN or MHb (25 pmol i.c.v.), it decreased methamphetamine self-administration, while not altering response to the sucrose. Interestingly, when delivered to the BLA, self-administration of both methamphetamine and sucrose decreased.62 Additionally, when AuIB was administered intracerebrally in mice chronically treated with morphine, physical withdrawal symptoms decreased, indicating that α3β4 is involved in the mechanisms of opioid withdrawal.138 Local infusion of AuIB in the MHb and IPN also had comparable results to mecamylamine in decreasing morphine self-administration.139 AuIB has also been applied to THC studies, where repeated THC doses were followed by AuIB (1.75-7 pmol i.c.v.), then challenged by rimonabant, a selective CB1 receptor antagonist.140 AuIB dose-dependently reduced signs of withdrawal caused by rimonabant, but gave no effect without the challenge. Taken together, the binding specificity of AuIB and its ability to modulate the effects of a variety of drugs of abuse indicates the importance of the α3β4 nAChR in addiction.
As is the case for many peptide-based drugs, the pharmacokinetics of the α-conotoxins represent a significant hurdle to their therapeutic development. Most notably, disulfide scrambling can change the bioactive conformation of the α-conotoxins and decrease their activity.141 To mitigate this problem, the Alewood group replaced cysteine with selenocysteine in a variety of α-conotoxins, including α3β4-active AuIB, BuIA, and Vc1.1, forming isosteric and nonreducible diselenide bonds.142 Scrambling was successfully prevented in these α-conotoxin analogues, even with just one diselenide bond, resulting in a 10-fold increase in potency compared to their native counterparts. Despite this, the analogues maintained a similar in vivo half-life compared to the parent compound, suggesting degradation of these peptides also occurs through other, likely enzymatic, pathways. Additionally, α-conotoxins are also limited by their poor permeability across the BBB to reach α3β4 nAChRs in the CNS. Although previous in vivo studies have bypassed this issue using intracerebroventricular or direct infusions into specific brain regions, the necessity to use similar routes of administration in the clinic represents a significant challenge to developing an α-conotoxin-based treatment for SUDs.
AZABICYCLIC PARTIAL AGONISTS
The effects of the naturally-occurring α3β4 nAChR inhibitors and existing nAChR channel blockers in animal models of SUDs have also prompted drug discovery campaigns targeting α3β4 nAChRs. Ultimately, these efforts led to the discovery of the azabicyclic small molecules represented by AT-1001 (Astraea Therapeutics), PF-4575180 (Pfizer), and CP-601932 (Pfizer). Notably, these molecules differ from other α3β4 ligands in that they produce partial activation of the receptors. Two azabicyclic α3β4 partial agonists have been investigated clinically with one completing a clinical study (CP-601932) and another (from Astraea Therapeutics) currently involved in a clinical study.143 The data generated by these azabicyclic small molecules indicate partial activation of the α3β4 nAChR as a viable mechanism for treating SUDs.
AT-1001
The development of AT-1001 began in 2010 with the discovery of SR16584, which was identified as an α3β4-selective ligand (Figure 5).144 Interestingly, this same scaffold is present in granisetron, an antagonist of 5-HT3, which is also a member of the Cys-loop family of ligand-gated ion channels. SR16584 has a similar affinity as nicotine at the α3β4 nAChR but lacks affinity for the α4β2 or α7 subtypes.144 Structure-activity relationship studies revealed that larger bicyclic rings led to increased selectivity at the α3β4 nAChR, suggesting the orthosteric binding site in α3β4 was larger than other nAChR subtypes. Indeed, this was later confirmed when a structure of the α3β4 nAChR was solved by cryogenic electron microscopy.37 Additionally, replacement of the dihydroindolin-2-one in SR16584 with a 2-bromophenyl led to the discovery of AT-1001, a high affinity α3β4 ligand with impressive subtype selectivity.144,145 Moreover, a screen of 48 CNS receptors identified interactions with only six non-nAChR receptor targets with binding affinities below 1 μM (Table 1).145 Comparatively, AT-1001 possesses 20-times greater affinity for α3β4 nAChR than these other CNS receptors. The high selectivity of this scaffold for the α3β4 nAChRs is also reflected in vivo; [125I]AT-1012, an iodine-containing derivative of AT-1001, traced drug localization in the CNS heavily to the MHb, IPN, FR, and pineal gland, which are structures known to contain high concentrations of α3β4 nAChRs (Figure 5).146
Figure 5.

Azabicyclic compounds SR16584, AT-1001, and AT-1012.
SR16584 and AT1001 were initially characterized as potent α3β4 antagonists based on their ability to inhibit epibatidine-induced activation of the receptors. In Scatchard analyses, SR16584 and AT-1001 both produced changes in epibatidine Kd and Bmax, suggesting they bind non-competitively with epibatidine (i.e., binding outside the orthosteric binding site).147 In a calcium flux assay, increasing concentrations of AT-1001 similarly lowered epibatidine’s Emax rather than producing a parallel shift in epibatidine dose-response curves, as would be expected for a non-competitive antagonist. Despite these initial results, later studies revealed that AT-1001 actually induces rapid, but partial, activation of the receptor and stabilizes the desensitized state, which ultimately inhibits the receptor from being activated by other agonists like epibatidine or acetylcholine. Moreover, a recent cryo-electron microscopy structure of AT-1001 bound to the desensitized state of the α3β4 receptor provides definitive evidence that it binds to the orthosteric site; clear electron density corresponding to AT-1001 is observed at both of the α3-β4 interfaces.37 Like nicotine, the AT-1001 cationic nitrogen forms a hydrogen bond with the carbonyl of W149 and cation-π interactions with the aromatic box motif.37 These residues are highly conserved within the orthosteric site of all nAChR subtypes and similar interactions are observed with other agonists at α4β2 and α3β4 nAChRs.37 Interestingly, a recent study using fluorinated, non-canonical amino acid incorporation suggests that these hydrogen-bond and cation-π interactions are weaker in AT-1001 compared to other nAChR agonists such as cytisine and acetylcholine.148 To explain the high subtype-selectivity of AT-1001, Hibbs and co-workers compared the binding pockets of the α3β4 and α4β2 nAChRs and found that the α3β4 site is slightly larger and proposed that steric interactions from the bromine in AT-1001 hinder it from binding to α4β2. Single-site mutagenesis by Knox et. al. revealed two amino acids to be particularly important for dictating this subtype selectivity. They found mutating Leu121 in β4 to phenylalanine present in β2 led to a 3-fold loss in potency, likely due to steric clash between the bromine atom and the large phenylalanine side chain.148 Decreasing the steric bulk in the binding site by mutating Ile113 to the smaller valine found in β2 also led to a decrease in potency, indicating that AT-1001 forms important hydrophobic interactions with the complementary face of the binding site. Taken together, these structural biology and mutagenesis studies highlight how even subtle changes in the highly conserved orthosteric binding site might be exploited to create highly subtype-selective ligands.
Although AT-1001 is a partial agonist, it produces similar effects as α3β4 nAChR antagonists in animal models of SUDs. In rats, AT-1001 (0.1-10 mg/kg s.c.) significantly and dose-dependently reduced nicotine self-administration.145 AT-1001 (0.75-3 mg/kg s.c.) also prevented nicotine reinstatement invoked by nicotine, varenicline, and the chemical stressor yohimbine.149 AT-1001 (1-10 mg/kg s.c.) decreased CPP and behavioral sensitization to cocaine (5 mg/kg s.c.).45 In addition to its effects on stimulants, AT-1001 also has been shown to modulate alcohol drinking in rats; AT-1001 (3 mg/kg s.c.) treatment results in a significant reduction in alcohol consumption.150 However, at this dose, AT-1001 also produced a decrease in food self-administration. A lower dose of AT-1001 (1.5 mg/kg s.c.) that did not reduce food intake, eliminated alcohol self-administration induced by the chemical stressor yohimbine. This effect appears to be limited to stress-induced reinstatement of alcohol seeking, since AT-1001 had no effect on cue-induced (light and odor) reinstatement of alcohol.150 This same study also demonstrated, when nicotine and alcohol are operantly co-administered, AT-1001 (1.5 mg/kg s.c.) does not decrease alcohol self-administration, but significantly decreases nicotine self-administration.150 This inability to reduce ethanol self-administration in the presence of nicotine may suggest the need for further testing in modes for polysubstance use disorder.
In addition to modulating the rewarding effects of nicotine, cocaine, and alcohol, AT-1001 has also been shown to decrease withdrawal symptoms of THC and opioids. In a study examining naloxone-induced morphine withdrawal in rats, AT-1001 (1-3 mg/kg i.c.v.) pre-administration significantly decreased somatic symptoms of withdrawal (paw tremors, head shaking, backing, ptosis, writhing, jumping, body tremor, diarrhea occurrence).138 Similarly, AT-1001 was able to decrease rimonabant-induced THC withdrawal (0.3, 3 mg/kg i.p.).140 The ability of AT-1001 to attenuate symptoms of withdrawal highlights the potential of α3β4 nAChR as a target to treat SUDs, as reduction of withdrawal symptoms would be expected to reduce rates of relapse in patients. Based on these promising results observed with AT-1001, Astraea Therapeutics has recently advanced an α3β4 nAChR partial agonist, AT-1082, into clinical trials as a novel smoking cessation agent.143
PF-4575180 and CP-601932
Concurrent with the discovery of AT-1001, Pfizer developed two potent α3β4 nAChR partial agonists, PF-4575180 and CP-601932 (Figure 6).151-153 Both molecules are structurally related to the FDA-approved smoking cessation drug varenicline, which in turn was derived from the alkaloid cytisine (Figure 6). Notably, while varenicline has a strong preference for the α4β2 subtype, it does possess significant affinity for the α3β4 subtype that may contribute to its mechanism of action. The success of varenicline, both in the clinic and as a tool for studying nAChR pharmacology, prompted further exploration of the scaffold in hopes of discovering other subtype-specific ligands.153 Compared to varenicline, CP-601932 has increased α3β4 nAChR affinity, reduced α4β2 affinity, and no α4β2 nAChR intrinsic activity.154 Calcium flux assays identified CP-601932 as a partial agonist at the α3β4 nAChR, and, like AT-1001 and PF-4575180, it is thought to stabilize the desensitized state of the α3β4 nAChR. Additional pursuits to discover subtype-selective nAChR ligands resulted in PF-4575180. PF-4575180 replaced the fused heterocycle found in varenicline or CP-601932 with an ortho-substituted-phenyl group appended to the azabicyclic ring system through an ether linkage.153 PF-4575180 possesses greater affinity, increased intrinsic activity, and more potent antagonism at the α3β4 nAChR than CP-601932, with no significant affinity or activity at α4β2.
Figure 6.

Azabicyclic compounds cytisine, varenicline, PF-4575180, and CP-601932.
So far, CP-601932 and PF-4575180 have only been investigated in animal models of alcohol use disorder where they were effective at reducing alcohol-seeking behavior. CP-601932 and PF-4575180 (10 mg/kg s.c.) observed a significant reduction in rat ethanol intake in both operant conditioning and intermittent two-bottle choice paradigms.155 Interestingly, at doses that were effective at reducing drinking, the unbound brain concentrations of CP-601932 and PF-4575180 correlated to in vitro concentrations that would inhibit most α3β4 nAChRs while leaving some persistently activated, highlighting the differences between partial agonists and antagonists. However, it is unclear how or whether persistent activation of α3β4 nAChRs will influence the effectiveness of treating SUDs.
In addition to these pre-clinical results for alcohol use disorders, CP-601932 has been investigated in the clinic as a smoking cessation therapy: in Phase 2 clinical trials, it was equal to or less effective than nicotine replacement therapy, cytisine, or varenicline. Together, the results from AT-1001, PF4575180, and CP-601932 indicate that α3β4 nAChR partial agonists perform similarly to α3β4 antagonists in animal models of SUD. This, in turn, suggests that by stabilizing the desensitized state of the receptor, these partial agonist act as functional antagonists in vivo by blocking the activation of the receptor by endogenous acetylcholine.
Summary and Outlook for α3β4 Inhibitors
When ibogaine made its way from relative obscurity around the middle of the last century, it set in motion an entire area of research. The early anecdotal reports of ibogaine’s ability to interrupt the addictive properties of numerous drugs of abuse sparked initial efforts to recapitulate these effects in laboratory models of SUDs and to search for derivatives with improved side effect profiles. This approach—human studies before animal models and compound optimization—runs counter to most modern drug discovery workflows, but it is not uncommon in the discovery of medically useful natural products. Indeed, some of the most widely used natural product-derived drugs, like morphine, were in use long before their biological targets were identified. Natural products have historically served as important chemical and pharmacological probes for revealing potential drug targets and biological pathways for additional drug discovery efforts.156 Ibogaine, it seems, follows this tradition. However, despite ibogaine and 18-MC being effective in numerous animal models of SUDs, their affinity for multiple CNS receptors, including those that have been implicated in drug abuse (e.g., κ opioid receptor), makes it difficult to assign this anti-addictive phenotype to a single target. Nevertheless, without the discovery of 18-MC and its ability to inhibit α3β4 nAChRs, one questions whether the role of α3β4 nAChRs in modulating the effects of drugs of abuse would have ever been fully appreciated.
In the decades since α3β4 nAChR was implicated in 18-MC’s mechanism of action, additional α3β4-targeting compounds have been discovered. Each of these drug classes has proven quite effective at modulating the effects of nearly every drug of abuse in rodents, strongly supporting α3β4 nAChRs as a bona fide target for the treatment of SUDs. Despite the abundance of data from animal models, only ibogaine and mecamylamine have been clinically investigated. As we have detailed above, each of the existing classes of α3β4 nAChR inhibitors possesses unique limitations that stand as translational hurdles. From these compounds, we conclude that the optimal α3β4-based therapy for SUDs should have: 1) high potency for antagonizing the α3β4 nAChR; 2) limited affinity for other nAChR subtypes and off-target receptors; 3) the ability to cross the blood-brain barrier with limited efflux; 4) prolonged plasma and metabolic stability; and 5) ideally, high oral-bioavailability.
With a cryo-EM structure of the α3β4 nAChR now available,37 the development of the next generation of α3β4-targeting compounds that meet these criteria will likely benefit greatly from structure-based design approaches. These approaches, of course, require a clearly defined binding site. And while computational studies have been used to propose binding sites for α3β4 ligands, experimental evidence from mutated receptors and the incorporation of non-natural amino acids has proven considerably more useful in defining the ligand-receptor interactions that dictate ligand binding.148 In addition to developing the existing classes of α3β4 nAChR inhibitors, it is also important to continue to identify and explore new chemotypes that target these receptors. Given that most α3β4-targeting compounds are derived from alkaloids (e.g. ibogaine, cytisine) or naturally occurring peptide toxins, natural products are likely to be a fruitful source of new compounds. Indeed, the recent discovery of several natural products, including the Aristotelia alkaloids, philanthotoxins, and ladybird alkaloids, with α3β4-subtype selectivity indicates that promising new classes of compounds ripe for further development may already exist.157-160
The estimated 35 million people suffering from an SUD worldwide underscores the urgent need to develop medications for SUDs.161 Even in the case of nicotine-, alcohol-, and opioid-use disorders where FDA-approved treatments exist, relapse rates remain high, patient compliance can be low, and drug-related deaths continue to rise. For other drugs of abuse, like cocaine and methamphetamine, there are no available pharmacotherapies, leaving millions of individuals without a medical treatment. Results from preclinical animal models and limited clinical data clearly suggest α3β4 nAChR inhibitors hold promise to address this rising need. Furthermore, polysubstance abuse is prevalent; for example, in a recent survey of women who used opioids for nonmedical purposes, 56.2% were cigarette smokers, 32.4% used marijuana, and 49.7% binge drank alcohol.161 Because α3β4 inhibitors appear effective against multiple drugs of abuse, they may be uniquely suited to treat co-morbid SUDs. The α3β4 inhibitors discussed here—as well as future compounds developed with the lessons gleaned from them—represent promising opportunities to test this therapeutic hypothesis. Moreover, given the encouraging results with the first generations of α3β4-targeting compounds, continued drug discovery efforts on this target have the potential to provide a new and much-needed treatment option for SUDs.
ACKNOWLEDGMENTS
The authors would like to thank Dr. Terry Moore for constructive and thoughtful feedback in preparation of this manuscript. The authors acknowledge the National Institute of General Medicine (R35GM147005) for generous financial support for this project. Additional support was provided by the National Center for Advancing Translational Sciences (KL2TR002002 to APR) and National Center for Complementary and Integrated Health (T32AT007533 to LER).
ABBREVIATIONS
- 18-MC
18-methoxycoronaridine
- AChBP
acetylcholine binding protein
- BBB
blood-brain barrier
- BID
twice per day
- CNS
central nervous system
- CPP
conditioned place preference
- DA
dopaminergic
- i.c.v.
intracerebroventricular
- i.m.
intramuscular
- i.p.
intraperitoneal
- IPN
interpeduncular nucleus
- i.v.
intravenous
- MEC
mecamylamine
- MHb
medial habenula
- nAChR
nicotinic acetylcholine receptor
- s.c.
subcutaneous
- SUD
substance use disorder
- VTA
ventral tegmental area
Biographies
Carolyn J. Straub earned her B.A. in Chemistry from Roosevelt University in 2017. After working as an analytical food chemist at Deibel Laboratories, she enrolled at the University of Illinois at Chicago. She is currently a Ph.D. candidate in Dr. Andrew Riley’s lab in UIC’s Department of Pharmaceutical Sciences. Her research explores the exciting chemical space of natural products, focusing primarily on the optimization and mechanistic study of their synthetic routes.
Lisa E. Rusali graduated from California State University, Long Beach in 2020 with a B.S. in Molecular Cell Biology and Physiology and a minor in Chemistry. She is now a Ph.D. candidate and NCCIH T32 Predoctoral Fellow at the University of Illinois at Chicago, under the supervision of Dr. Andrew Riley, where she works on the development and evaluation of CNS-targeting compounds derived from alkaloid natural products.
Kyle M. Kremiller graduated from Rutgers University Honors College, New Brunswick in 2019 with a B.A. in Genetics. He is currently a M.D./Ph.D. candidate at the University of Illinois at Chicago, in the Medical Scientist Training Program. He is currently in his Ph.D. phase and is part of Dr. Andrew Riley’s lab in UIC’s Department of Pharmaceutical Sciences. He focuses on developing new methods to screen compounds and chemically optimizing them to develop useful molecular probes and potential therapeutics that target the nAChRs.
Andrew P. Riley is an assistant professor in the Department of Pharmaceutical Sciences at the University of Illinois, Chicago. He earned his bachelor’s degree from Ohio Wesleyan University and Ph.D. at the University of Kansas in 2015 and conducted postdoctoral studies at the University of Illinois, Urbana-Champaign as an NIH National Research Service Program Fellow. In 2018, Dr. Riley began his independent career at UIC where he and his research team have been investigating small-molecules that target GPCRs and ion channels involved in pain and addiction.
Footnotes
The authors declare no competing financial interest.
References
- 1.Fernandez JW; Fernandez RL Bwiti; An Ethnography of the Religious Imagination in Africa; Princeton University Press: 1982; . [Google Scholar]
- 2.Glick SD; Maisonneuve IM Development of Novel Medications for Drug Addiction: The Legacy of an African Shrub. Ann. N. Y. Acad. Sci 2000, 909, 88–103. [DOI] [PubMed] [Google Scholar]
- 3.Alper KR; Lotsof HS; Kaplan CD The ibogaine medical subculture. J. Ethnopharmacol 2008, 115, 9–24. [DOI] [PubMed] [Google Scholar]
- 4.Lotsof HS; Alexander NE Case studies of ibogaine treatment: implications for patient management strategies. Alkaloids Chem. Biol 2001, 56, 293–313. [DOI] [PubMed] [Google Scholar]
- 5.Lotsof HS United States Patent 4,499,096, 1985.
- 6.Lotsof HS United States Patent 5,026,697, 1991.
- 7.Lotsof HS United States Patent 4,857,523, 1989.
- 8.Lotsof HS United States Patent 4,587,243, 1986.
- 9.Lotsof HS United States Patent 5,124,994, 1992.
- 10.Abrams M The Biology of . . . Addiction. https://www.discovermagazine.com/mind/the-biology-of-addiction. [Google Scholar]
- 11.Glick SD; Kuehne ME; Raucci J; Wilson TE; Larson D; Keller RW Jr; Carlson JN Effects of iboga alkaloids on morphine and cocaine self-administration in rats: relationship to tremorigenic effects and to effects on dopamine release in nucleus accumbens and striatum. Brain Res. 1994, 657, 14–22. [DOI] [PubMed] [Google Scholar]
- 12.Rezvani AH; Overstreet DH; Yang Y; Maisonneuve IM; Bandarage UK; Kuehne ME; Glick SD Attenuation of Alcohol Consumption by a Novel Nontoxic Ibogaine Analogue (18-Methoxycoronaridine) in Alcohol-Preferring Rats. Pharmacology Biochemistry and Behavior 1997, 58, 615–619. [DOI] [PubMed] [Google Scholar]
- 13.Glick SD; Maisonneuve IM; Visker KE; Fritz KA; Bandarage UK; Kuehne ME 18-Methoxycoronardine attenuates nicotine-induced dopamine release and nicotine preferences in rats. Psychopharmacology (Berl. ) 1998, 139, 274–280. [DOI] [PubMed] [Google Scholar]
- 14.Meisner JA; Wilcox SR; Richards JB Ibogaine-associated cardiac arrest and death: case report and review of the literature. Ther. Adv. Psychopharmacol 2016, 6, 95–98. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Koenig X; Hilber K The Anti-Addiction Drug Ibogaine and the Heart: A Delicate Relation. Molecules 2015, 20, 2208–2228. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Glick SD; Kuehne ME; Maisonneuve IM; Bandarage UK; Molinari HH 18-Methoxycoronaridine, a non-toxic iboga alkaloid congener: effects on morphine and cocaine self-administration and on mesolimbic dopamine release in rats. Brain Res. 1996, 719, 29–35. [DOI] [PubMed] [Google Scholar]
- 17.Glick SD; Maisonneuve IM; Hough LB; Kuehne ME; Bandarage UK (±)-18-Methoxycoronaridine: A Novel Iboga Alkaloid Congener Having Potential Anti-Addictive Efficacy. CNS Drug Rev. 1999, 5, 27–42. [Google Scholar]
- 18.Alper K; Bai R; Liu N; Fowler SJ; Huang X; Priori SG; Ruan Y hERG Blockade by Iboga Alkaloids. Cardiovascular Toxicology 2016, 16, 14–22. [DOI] [PubMed] [Google Scholar]
- 19.Glick SD; Maisonneuve IM; Szumlinski KK 18-Methoxycoronaridine (18-MC) and ibogaine: comparison of antiaddictive efficacy, toxicity, and mechanisms of action. Ann. N. Y. Acad. Sci 2000, 914, 369–386. [DOI] [PubMed] [Google Scholar]
- 20.Burckhardt CA; Goutarel R; Janot MM; Schlittler E Ibogamin, ein neues Alkaloid aus Tabernanthe Iboga Baillon. HCA 1952, 35, 642–643. [Google Scholar]
- 21.Glick SD; Maisonneuve IM; Kitchen BA; Fleck MW Antagonism of α3β4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. Eur. J. Pharmacol 2002, 438, 99–105. [DOI] [PubMed] [Google Scholar]
- 22.Kosten TR; Kleber HD; Morgan C Role of opioid antagonists in treating intravenous cocaine abuse. Life Sci. 1989, 44, 887–892. [DOI] [PubMed] [Google Scholar]
- 23.Taraschenko OD; Panchal V; Maisonneuve IM; Glick SD Is antagonism of α3β4 nicotinic receptors a strategy to reduce morphine dependence? Eur. J. Pharmacol 2005, 513, 207–218. [DOI] [PubMed] [Google Scholar]
- 24.Pace CJ; Glick SD; Maisonneuve IM; He L; Jokiel PA; Kuehne ME; Fleck MW Novel iboga alkaloid congeners block nicotinic receptors and reduce drug self-administration. Eur. J. Pharmacol 2004, 492, 159–167. [DOI] [PubMed] [Google Scholar]
- 25.Rush R; Kuryatov A; Nelson ME; Lindstrom J First and second transmembrane segments of alpha3, alpha4, beta2, and beta4 nicotinic acetylcholine receptor subunits influence the efficacy and potency of nicotine. Mol. Pharmacol 2002, 61, 1416–1422. [DOI] [PubMed] [Google Scholar]
- 26.Luetje CW; Patrick J Both alpha- and beta-subunits contribute to the agonist sensitivity of neuronal nicotinic acetylcholine receptors. J. Neurosci 1991, 11, 837–845. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Harvey SC; Luetje CW Determinants of Competitive Antagonist Sensitivity on Neuronal Nicotinic Receptor β Subunits. J. Neurosci 1996, 16, 3798–3806. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Kuryatov A; Olale FA; Choi C; Lindstrom J Acetylcholine receptor extracellular domain determines sensitivity to nicotine-induced inactivation. Eur. J. Pharmacol 2000, 393, 11–21. [DOI] [PubMed] [Google Scholar]
- 29.Bertrand D Neuronal Nicotinic Acetylcholine Receptors and Epilepsy. Epilepsy Curr. 2002, 2, 191–193. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Wu J; Ishikawa M; Zhang J; Hashimoto K Brain imaging of nicotinic receptors in Alzheimer's disease. Int. J. Alzheimers Dis 2010, 2010, 548913. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Quik M; Bordia T; Huang L; Perez X Targeting nicotinic receptors for Parkinson's disease therapy. CNS Neurol. Disord. Drug Targets 2011, 10, 651–658. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Gotti C; Zoli M; Clementi F Brain nicotinic acetylcholine receptors: native subtypes and their relevance. Trends Pharmacol. Sci 2006, 27, 482–491. [DOI] [PubMed] [Google Scholar]
- 33.Parikh V; Kutlu MG; Gould TJ nAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives. Schizophr. Res 2016, 171, 1–15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Hone AJ; McIntosh JM Nicotinic acetylcholine receptors in neuropathic and inflammatory pain. FEBS Lett. 2018, 592, 1045–1062. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Leslie FM; Mojica CY; Reynaga DD Nicotinic receptors in addiction pathways. Mol. Pharmacol 2013, 83, 753–758. [DOI] [PubMed] [Google Scholar]
- 36.Exley R; Clements MA; Hartung H; McIntosh JM; Cragg SJ α6-Containing Nicotinic Acetylcholine Receptors Dominate the Nicotine Control of Dopamine Neurotransmission in Nucleus Accumbens. Neuropsychopharmacology 2008, 33, 2158–2166. [DOI] [PubMed] [Google Scholar]
- 37.Gharpure A; Teng J; Zhuang Y; Noviello CM; Walsh RM; Cabuco R; Howard RJ; Zaveri NT; Lindahl E; Hibbs RE Agonist Selectivity and Ion Permeation in the α3β4 Ganglionic Nicotinic Receptor. Neuron 2019, 104, 501–511.e6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Sine SM The nicotinic receptor ligand binding domain. J. Neurobiol 2002, 53, 431–446. [DOI] [PubMed] [Google Scholar]
- 39.Hansen SB; Sulzenbacher G; Huxford T; Marchot P; Taylor P; Bourne Y Structures of Aplysia AChBP complexes with nicotinic agonists and antagonists reveal distinctive binding interfaces and conformations. EMBO J. 2005, 24, 3635–3646. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Hansen SB; Taylor P Galanthamine and Non-competitive Inhibitor Binding to ACh-binding Protein: Evidence for a Binding Site on Non-α-subunit Interfaces of Heteromeric Neuronal Nicotinic Receptors. J. Mol. Biol 2007, 369, 895–901. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Perry DC; Xiao Y; Nguyen HN; Musachio JL; Dávila-García MI; Kellar KJ Measuring nicotinic receptors with characteristics of α4β2, α3β2 and α3β4 subtypes in rat tissues by autoradiography. J. Neurochem 2002, 82, 468–481. [DOI] [PubMed] [Google Scholar]
- 42.McLaughlin I; Dani JA; De Biasi M The medial habenula and interpeduncular nucleus circuitry is critical in addiction, anxiety, and mood regulation. J. Neurochem 2017, 142 Suppl 2, 130–143. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Lee HW; Yang SH; Kim JY; Kim H The Role of the Medial Habenula Cholinergic System in Addiction and Emotion-Associated Behaviors. Frontiers in Psychiatry 2019, 10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Hussain RJ; Taraschenko OD; Glick SD Effects of nicotine, methamphetamine and cocaine on extracellular levels of acetylcholine in the interpeduncular nucleus of rats. Neurosci. Lett 2008, 440, 270–274. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Khroyan TV; Yasuda D; Toll L; Polgar WE; Zaveri NT High affinity α3β4 nicotinic acetylcholine receptor ligands AT-1001 and AT-1012 attenuate cocaine-induced conditioned place preference and behavioral sensitization in mice. Biochemical Pharmacology 2015, 97, 531–541. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Glick SD; Maisonneuve IM; Raucci J; Archer S Kappa opioid inhibition of morphine and cocaine self-administration in rats. Brain Res. 1995, 681, 147–152. [DOI] [PubMed] [Google Scholar]
- 47.Cameron LP; Tombari RJ; Lu J; Pell AJ; Hurley ZQ; Ehinger Y; Vargas MV; McCarroll MN; Taylor JC; Myers-Turnbull D; Liu T; Yaghoobi B; Laskowski LJ; Anderson EI; Zhang G; Viswanathan J; Brown BM; Tjia M; Dunlap LE; Rabow ZT; Fiehn O; Wulff H; McCorvy JD; Lein PJ; Kokel D; Ron D; Peters J; Zuo Y; Olson DE A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature 2021, 589, 474–479. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Glick S; Maisonneuve I Mechanisms of Antiaddictive Actions of Ibogaine. Ann. N. Y. Acad. Sci 1998, 844, 214–226. [PubMed] [Google Scholar]
- 49.Bandarage UK; Kuehne ME; Glick SD Total syntheses of racemic albifloranine and its anti-addictive congeners, including 18-methoxycoronaridine. Tetrahedron 1999, 55, 9405–9424. [Google Scholar]
- 50.Kuehne ME; Wilson TE; Bandarage UK; Dai W; Yu Q Enantioselective syntheses of coronaridine and 18-methoxycoronaridine. Tetrahedron 2001, 57, 2085–2094. [Google Scholar]
- 51.O'Hearn E; Long DB; Molliver ME Ibogaine induces glial activation in parasagittal zones of the cerebellum. Neuroreport 1993, 4. [DOI] [PubMed] [Google Scholar]
- 52.Molinari HH; Maisonneuve IM; Glick SD Ibogaine neurotoxicity: a re-evaluation. Brain Res. 1996, 737, 255–262. [DOI] [PubMed] [Google Scholar]
- 53.O'Hearn E; Molliver ME Degeneration of Purkinje cells in parasagittal zones of the cerebellar vermis after treatment with ibogaine or harmaline. Neuroscience 1993, 55, 303–310. [DOI] [PubMed] [Google Scholar]
- 54.Freeman S; Reele SB; Bonelle J United States Patent WO 2021/067549 A1, 2021.
- 55.Badio B; Padgett WL; Daly JW Ibogaine: A Potent Noncompetitive Blocker of Ganglionic/Neuronal Nicotinic Receptors. Mol. Pharmacol 1997, 51, 1–5. [DOI] [PubMed] [Google Scholar]
- 56.Arias HR; Rosenberg A; Targowska-Duda KM; Feuerbach D; Yuan XJ; Jozwiak K; Moaddel R; Wainer IW Interaction of ibogaine with human alpha3beta4-nicotinic acetylcholine receptors in different conformational states. Int. J. Biochem. Cell Biol 2010, 42, 1525–1535. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Arias HR; Targowska-Duda KM; Feuerbach D; Jozwiak K Coronaridine congeners inhibit human α3β4 nicotinic acetylcholine receptors by interacting with luminal and non-luminal sites. Int. J. Biochem. Cell Biol 2015, 65, 81–90. [DOI] [PubMed] [Google Scholar]
- 58.Rezvani AH; Cauley MC; Slade S; Wells C; Glick S; Rose JE; Levin ED Acute oral 18-methoxycoronaridine (18-MC) decreases both alcohol intake and IV nicotine self-administration in rats. Pharmacol. Biochem. Behav 2016, 150-151, 153–157. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Miller CN; Ruggery C; Kamens HM The α3β4 nicotinic acetylcholine receptor antagonist 18-Methoxycoronaridine decreases binge-like ethanol consumption in adult C57BL/6J mice. Alcohol 2019, 79, 1–6. [DOI] [PubMed] [Google Scholar]
- 60.Glick SD; Maisonneuve IM; Dickinson HA 18-MC reduces methamphetamine and nicotine self-administration in rats. Neuroreport 2000, 11, 2013–2015. [DOI] [PubMed] [Google Scholar]
- 61.Polston JE; Pritchett CE; Sell EM; Glick SD 18-Methoxycoronaridine blocks context-induced reinstatement following cocaine self-administration in rats. Pharmacol. Biochem. Behav 2012, 103, 83–94. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Glick SD; Sell EM; Maisonneuve IM Brain regions mediating α3β4 nicotinic antagonist effects of 18-MC on methamphetamine and sucrose self-administration. Eur. J. Pharmacol 2008, 599, 91–95. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Glick SD; Ramirez RL; Livi JM; Maisonneuve IM 18-Methoxycoronaridine acts in the medial habenula and/or interpeduncular nucleus to decrease morphine self-administration in rats. Eur. J. Pharmacol 2006, 537, 94–98. [DOI] [PubMed] [Google Scholar]
- 64.Arias HR; Jin X; Feuerbach D; Drenan RM Selectivity of coronaridine congeners at nicotinic acetylcholine receptors and inhibitory activity on mouse medial habenula. Int. J. Biochem. Cell Biol 2017, 92, 202–209. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Reid LD; Glick SD; Menkens KA; French ED; Bilsky EJ; Porreca F Cocaine self-administration and naltrindole, a delta-selective opioid antagonist. Neuroreport 1995, 6, 1409–1412. [DOI] [PubMed] [Google Scholar]
- 66.Mind Medicine (MindMed) Inc Opioid Use Disorder: Zolunicant’s Potential for Unmet Treatment Needs. https://mindmed.co/news/video/opioid-use-disorder-zolunicants-potential-for-unmet-treatment-needs/?playvideo=true (accessed September 13, 2022).
- 67.Young JM; Shytle DR; Sanberg PR; George TP Mecamylamine: new therapeutic uses and toxicity/risk profile. Clin. Ther 2001, 23, 532–565. [DOI] [PubMed] [Google Scholar]
- 68.Webster JC; Francis MM; Porter JK; Robinson G; Stokes C; Horenstein B; Papke RL Antagonist activities of mecamylamine and nicotine show reciprocal dependence on beta subunit sequence in the second transmembrane domain. Br. J. Pharmacol 1999, 127, 1337–1348. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Waterhouse RN Imaging the PCP site of the NMDA ion channel. Nucl. Med. Biol 2003, 30, 869–878. [DOI] [PubMed] [Google Scholar]
- 70.Lee KS; Tsien RW Mechanism of calcium channel blockade by verapamil, D600, diltiazem and nitrendipine in single dialysed heart cells. Nature 1983, 302, 790–794. [DOI] [PubMed] [Google Scholar]
- 71.Lingle C Different types of blockade of crustacean acetylcholine-induced currents. J. Physiol. (Lond. ) 1983, 339, 419–437. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.Ostroumov K; Shaikhutdinova A; Skorinkin A Modeling study of mecamylamine block of muscle type acetylcholine receptors. Eur. Biophys. J 2008, 37, 393–402. [DOI] [PubMed] [Google Scholar]
- 73.Giniatullin RA; Sokolova EM; Di Angelantonio S; Skorinkin A; Talantova MV; Nistri A Rapid Relief of Block by Mecamylamine of Neuronal Nicotinic Acetylcholine Receptors of Rat Chromaffin Cells In Vitro: An Electrophysiological and Modeling Study. Mol. Pharmacol 2000, 58, 778–787. [DOI] [PubMed] [Google Scholar]
- 74.Martin BR; Onaivi ES; Martin TJ What is the nature of mecamylamine's antagonism of the central effects of nicotine? Biochem. Pharmacol 1989, 38, 3391–3397. [DOI] [PubMed] [Google Scholar]
- 75.Suchocki JA; May EL; Martin TJ; George C; Martin BR Synthesis of 2-exo- and 2-endo-mecamylamine analogs. Structure-activity relationships for nicotinic antagonism in the central nervous system. J. Med. Chem 1991, 34, 1003–1010. [DOI] [PubMed] [Google Scholar]
- 76.Banerjee S; Punzi JS; Kreilick K; Abood LG [3H]mecamylamine binding to rat brain membranes: Studies with mecamylamine and nicotine analogues. Biochem. Pharmacol 1990, 40, 2105–2110. [DOI] [PubMed] [Google Scholar]
- 77.Stone CA; Torchiana ML; Meckelnberg KL; Stavorski J; Sletzinger M; Stein GA; Ruyle WV; Reinhold DF; Gaines WA; Arnold H; Pfister K III Chemistry and Structure-Activity Relationships of Mecamylamine and Derivatives. J. Med. Pharm. Chem 1962, 91, 665–690. [DOI] [PubMed] [Google Scholar]
- 78.Papke RL; Sanberg PR; Shytle RD Analysis of Mecamylamine Stereoisomers on Human Nicotinic Receptor Subtypes. J. Pharmacol. Exp. Ther 2001, 297, 646–656. [PubMed] [Google Scholar]
- 79.Fedorov NB; Benson LC; Graef J; Lippiello PM; Bencherif M Differential Pharmacologies of Mecamylamine Enantiomers: Positive Allosteric Modulation and Noncompetitive Inhibition. J. Pharmacol. Exp. Ther 2009, 328, 525–532. [DOI] [PubMed] [Google Scholar]
- 80.Lippiello PM; Beaver JS; Gatto GJ; James JW; Jordan KG; Traina VM; Xie J; Bencherif M TC-5214 (S-(+)-Mecamylamine): A Neuronal Nicotinic Receptor Modulator with Antidepressant Activity. CNS Neuroscience & Therapeutics 2008, 14, 266–277. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 81.Klink R; d'Exaerde A. d. K.; Zoli M; Changeux J Molecular and Physiological Diversity of Nicotinic Acetylcholine Receptors in the Midbrain Dopaminergic Nuclei. J. Neurosci 2001, 21, 1452–1463. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 82.Quick MW; Ceballos RM; Kasten M; McIntosh JM; Lester RA α3β4 subunit-containing nicotinic receptors dominate function in rat medial habenula neurons. Neuropharmacology 1999, 38, 769–783. [DOI] [PubMed] [Google Scholar]
- 83.Shoaib M; Schindler CW; Goldberg SR Nicotine self-administration in rats: strain and nicotine pre-exposure effects on acquisition. Psychopharmacology (Berl) 1997, 129, 35–43. [DOI] [PubMed] [Google Scholar]
- 84.Stolerman IP; Naylor C; Elmer GI; Goldberg SR Discrimination and self-administration of nicotine by inbred strains of mice. Psychopharmacology (Berl) 1999, 141, 297–306. [DOI] [PubMed] [Google Scholar]
- 85.Watkins SS; Epping-Jordan MP; Koob GF; Markou A Blockade of Nicotine Self-Administration with Nicotinic Antagonists in Rats. Pharmacology Biochemistry and Behavior 1999, 62, 743–751. [DOI] [PubMed] [Google Scholar]
- 86.Blokhina EA; Kashkin VA; Zvartau EE; Danysz W; Bespalov AY Effects of nicotinic and NMDA receptor channel blockers on intravenous cocaine and nicotine self-administration in mice. European Neuropsychopharmacology 2005, 15, 219–225. [DOI] [PubMed] [Google Scholar]
- 87.Liu X; Caggiula AR; Yee SK; Nobuta H; Sved AF; Pechnick RN; Poland RE Mecamylamine Attenuates Cue-Induced Reinstatement of Nicotine-Seeking Behavior in Rats. Neuropsychopharmacology 2007, 32, 710–718. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88.Fowler CD; Kenny PJ Intravenous nicotine self-administration and cue-induced reinstatement in mice: Effects of nicotine dose, rate of drug infusion and prior instrumental training. Neuropharmacology 2011, 61, 687–698. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 89.Corrigall WA; Coen KM Nicotine maintains robust self-administration in rats on a limited-access schedule. Psychopharmacology (Berl) 1989, 99, 473–478. [DOI] [PubMed] [Google Scholar]
- 90.Risner ME; Goldberg SR A comparison of nicotine and cocaine self-administration in the dog: fixed-ratio and progressive-ratio schedules of intravenous drug infusion. J. Pharmacol. Exp. Ther 1983, 224, 319–326. [PubMed] [Google Scholar]
- 91.Spealman RD; Goldberg SR Maintenance of schedule-controlled behavior by intravenous injections of nicotine in squirrel monkeys. J. Pharmacol. Exp. Ther 1982, 223, 402–408. [PubMed] [Google Scholar]
- 92.Levin ED; Mead T; Rezvani AH; Rose JE; Gallivan C; Gross R The nicotinic antagonist mecamylamine preferentially inhibits cocaine vs. food self-administration in rats. Physiol. Behav 2000, 71, 565–570. [DOI] [PubMed] [Google Scholar]
- 93.Hendrickson LM; Zhao-Shea R; Tapper AR Modulation of ethanol drinking-in-the-dark by mecamylamine and nicotinic acetylcholine receptor agonists in C57BL/6J mice. Psychopharmacology (Berl. ) 2009, 204, 563–572. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 94.Lě AD; Corrigall WA; Watchus J; Harding S; Juzytsch W; Li T -. Involvement of Nicotinic Receptors in Alcohol Self-Administration. Alcoholism: Clinical and Experimental Research 2000, 24, 155–163. [DOI] [PubMed] [Google Scholar]
- 95.Kuzmin A; Jerlhag E; Liljequist S; Engel J Effects of subunit selective nACh receptors on operant ethanol self-administration and relapse-like ethanol-drinking behavior. Psychopharmacology (Berl) 2009, 203, 99–108. [DOI] [PubMed] [Google Scholar]
- 96.Ford MM; Fretwell AM; Nickel JD; Mark GP; Strong MN; Yoneyama N; Finn DA The influence of mecamylamine on ethanol and sucrose self-administration. Neuropharmacology 2009, 57, 250–258. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 97.Farook JM; Lewis B; Gaddis JG; Littleton JM; Barron S Effects of mecamylamine on alcohol consumption and preference in male C57BL/6J mice. Pharmacology 2009, 83, 379–384. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 98.Tennant FS; Tarver AL Withdrawal from nicotine dependence using mecamylamine: comparison of three-week and six-week dosage schedules. NIDA Res. Monogr 1984, 55, 291–297. [PubMed] [Google Scholar]
- 99.Tennant FS; Tarver AL; Rawson RA Clinical evaluation of mecamylamine for withdrawal from nicotine dependence. NIDA Res. Monogr 1984, 49, 239–246. [PubMed] [Google Scholar]
- 100.Rose JE; Behm FM; Westman EC; Levin ED; Stein RM; Ripka GV Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone. Clinical Pharmacology & Therapeutics 1994, 56, 86–99. [DOI] [PubMed] [Google Scholar]
- 101.Chi H; de Wit H Mecamylamine Attenuates the Subjective Stimulant-Like Effects of Alcohol in Social Drinkers. Alcoholism: Clinical and Experimental Research 2003, 27, 780–786. [DOI] [PubMed] [Google Scholar]
- 102.Blomqvist O; Hernandez-Avila C; Van Kirk J; Rose JE; Kranzler HR Mecamylamine Modifies the Pharmacokinetics and Reinforcing Effects of Alcohol. Alcoholism: Clinical and Experimental Research 2002, 26, 326–331. [PubMed] [Google Scholar]
- 103.Ralevski E; Jane JS; O’Brien E; Edens E; Arnaout B; Kerfoot K; Keegan K; Weiner J; Russo M; Petrakis I Mecamylamine for Treatment of People With Dual Diagnoses of Depression and Alcohol Dependence. Journal of Dual Diagnosis 2013, 9, 301–310. [Google Scholar]
- 104.Shytle RD; Silver AA; Lukas RJ; Newman MB; Sheehan DV; Sanberg PR Nicotinic acetylcholine receptors as targets for antidepressants. Mol. Psychiatry 2002, 7, 525–535. [DOI] [PubMed] [Google Scholar]
- 105.Shytle RD; Silver AA; Sheehan KH; Sheehan DV; Sanberg PR Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine. Depress. Anxiety 2002, 16, 89–92. [DOI] [PubMed] [Google Scholar]
- 106.Shytle RD; Penny E; Silver AA; Goldman J; Sanberg PR Mecamylamine (Inversine): an old antihypertensive with new research directions. J. Hum. Hypertens 2002, 16, 453–457. [DOI] [PubMed] [Google Scholar]
- 107.Jin A; Muttenthaler M; Dutertre S; Himaya SWA; Kaas Q; Craik DJ; Lewis RJ; Alewood PF Conotoxins: Chemistry and Biology. Chem. Rev 2019, 119, 11510. [DOI] [PubMed] [Google Scholar]
- 108.Layer R; McIntosh J Conotoxins: therapeutic potential and application. Marine Drugs 2006, 4, 119–142. [Google Scholar]
- 109.Lebbe EKM; Peigneur S; Wijesekara I; Tytgat J Conotoxins Targeting Nicotinic Acetylcholine Receptors: An Overview. Marine drugs 2014, 12, 2970–3004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 110.Livett BG; Sandall DW; Keays D; Down J; Gayler KR; Satkunanathan N; Khalil Z Therapeutic applications of conotoxins that target the neuronal nicotinic acetylcholine receptor. Toxicon (Oxford) 2006, 48, 810–829. [DOI] [PubMed] [Google Scholar]
- 111.Gao B; Peng C; Yang J; Yi Y; Zhang J; Shi Q Cone Snails: A Big Store of Conotoxins for Novel Drug Discovery. Toxins 2017, 9. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 112.Abraham N; Lewis RJ Neuronal Nicotinic Acetylcholine Receptor Modulators from Cone Snails. Marine Drugs 2018, 16. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 113.Jin A; Brandstaetter H; Nevin ST; Tan CC; Clark RJ; Adams DJ; Alewood PF; Craik DJ; Daly NL Structure of α-conotoxin BuIA: influences of disulfide connectivity on structural dynamics. BMC Structural Biology 2007, 7, 28. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 114.Kompella SN; Hung A; Clark RJ; Marí F; Adams DJ Alanine Scan of α-Conotoxin RegIIA Reveals a Selective α3β4 Nicotinic Acetylcholine Receptor Antagonist. The Journal of Biological Chemistry 2015, 290, 1039–1048. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 115.Tae H; Gao B; Jin A; Alewood PF; Adams DJ Globular and ribbon isomers of Conus geographus α-conotoxins antagonize human nicotinic acetylcholine receptors. Biochemical Pharmacology 2021, 190, 114638. [DOI] [PubMed] [Google Scholar]
- 116.Janes RW α-Conotoxins as selective probes for nicotinic acetylcholine receptor subclasses. Current Opinion in Pharmacology 2005, 5, 280–292. [DOI] [PubMed] [Google Scholar]
- 117.McIntosh JM; Santos AD; Olivera BM Conus Peptides Targeted to Specific Nicotinic Acetylcholine Receptor Subtypes. Annual review of biochemistry 1999, 68, 59–88. [DOI] [PubMed] [Google Scholar]
- 118.Luo S; Kulak JM; Cartier GE; Jacobsen RB; Yoshikami D; Olivera BM; McIntosh JM α-Conotoxin AuIB Selectively Blocks α3β4 Nicotinic Acetylcholine Receptors and Nicotine-Evoked Norepinephrine Release. The Journal of Neuroscience 1998, 18, 8571–8579. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 119.Grishin AA; Cuny H; Hung A; Clark RJ; Brust A; Akondi K; Alewood PF; Craik DJ; Adams DJ Identifying Key Amino Acid Residues That Affect α-Conotoxin AuIB Inhibition of α3β4 Nicotinic Acetylcholine Receptors. The Journal of Biological Chemistry 2013, 288, 34428–34442. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 120.Luo S; Zhangsun D; Zhu X; Wu Y; Hu Y; Christensen S; Harvey PJ; Akcan M; Craik DJ; McIntosh JM Characterization of a Novel α-Conotoxin TxID from Conus textile That Potently Blocks Rat α3β4 Nicotinic Acetylcholine Receptors. Journal of Medicinal Chemistry 2013, 56, 9655–9663. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 121.Grishin AA; Wang CA; Muttenthaler M; Alewood PF; Lewis RJ; Adams DJ α-Conotoxin AuIB Isomers Exhibit Distinct Inhibitory Mechanisms and Differential Sensitivity to Stoichiometry of α3β4 Nicotinic Acetylcholine Receptors. The Journal of Biological Chemistry 2010, 285, 22254–22263. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 122.Cuny H; Kompella SN; Tae H; Yu R; Adams DJ Key Structural Determinants in the Agonist Binding Loops of Human β2 and β4 Nicotinic Acetylcholine Receptor Subunits Contribute to α3β4 Subtype Selectivity of α-Conotoxins. The Journal of Biological Chemistry 2016, 291, 23779–23792. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 123.Franco A; Kompella SN; Akondi KB; Melaun C; Daly NL; Luetje CW; Alewood PF; Craik DJ; Adams DJ; Marí F RegIIA: An α4/7-conotoxin from the venom of Conus regius that potently blocks α3β4 nAChRs. Biochemical Pharmacology 2012, 83, 419–426. [DOI] [PubMed] [Google Scholar]
- 124.Abraham N; Healy M; Ragnarsson L; Brust A; Alewood PF; Lewis RJ Structural mechanisms for α-conotoxin activity at the human α3β4 nicotinic acetylcholine receptor. Scientific reports 2017, 7, 45466. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 125.Azam L; Dowell C; Watkins M; Stitzel JA; Olivera BM; McIntosh JM α-Conotoxin BuIA, a Novel Peptide from Conus bullatus, Distinguishes among Neuronal Nicotinic Acetylcholine Receptors. The Journal of Biological Chemistry 2005, 280, 80–87. [DOI] [PubMed] [Google Scholar]
- 126.Dowell C; Olivera BM; Garrett JE; Staheli ST; Watkins M; Kuryatov A; Yoshikami D; Lindstrom JM; McIntosh JM α-Conotoxin PIA Is Selective for α6 Subunit-Containing Nicotinic Acetylcholine Receptors. The Journal of Neuroscience 2003, 23, 8445–8452. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 127.McIntosh JM; Dowell C; Watkins M; Garrett JE; Yoshikami D; Olivera BM α-Conotoxin GIC from Conus geographus, a Novel Peptide Antagonist of Nicotinic Acetylcholine Receptors. The Journal of biological chemistry 2002, 277, 33610–33615. [DOI] [PubMed] [Google Scholar]
- 128.Luo S; Zhangsun D; Schroeder CI; Zhu X; Hu Y; Wu Y; Weltzin MM; Eberhard S; Kaas Q; Craik DJ; Mcintosh JM; Whiteaker P A novel α4/7-conotoxin LvIA from Conus lividus that selectively blocks α3β2 vs. α6/α3β2β3 nicotinic acetylcholine receptors. FASEB j. 2014, 28, 1842. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 129.Inserra MC; Kompella SN; Vetter I; Brust A; Daly NL; Cuny H; Craik DJ; Alewood PF; Adams DJ; Lewis RJ Isolation and characterization of α-conotoxin LsIA with potent activity at nicotinic acetylcholine receptors. Biochemical Pharmacology 2013, 86, 791–799. [DOI] [PubMed] [Google Scholar]
- 130.Wu Y; Zhangsun D; Zhu X; Kaas Q; Zhangsun M; Harvey PJ; Craik DJ; Mcintosh JM; Luo S α-Conotoxin [S9A]TxID Potently Discriminates between α3β4 and α6/α3β4 Nicotinic Acetylcholine Receptors. J. Med. Chem 2017, 60, 5826. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 131.Yu J; Zhu X; Harvey PJ; Kaas Q; Zhangsun D; Craik DJ; Luo S Single Amino Acid Substitution in α-Conotoxin TxID Reveals a Specific α3β4 Nicotinic Acetylcholine Receptor Antagonist. Journal of medicinal chemistry 2018, 61, 9256–9265. [DOI] [PubMed] [Google Scholar]
- 132.Chang Y; Banerjee J; Dowell C; Wu J; Gyanda R; Houghten RA; Toll L; McIntosh JM; Armishaw CJ Discovery of a Potent and Selective α3β4 Nicotinic Acetylcholine Receptor Antagonist from an α-Conotoxin Synthetic Combinatorial Library. Journal of medicinal chemistry 2014, 57, 3511–3521. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 133.McCallum SE; Cowe MA; Lewis SW; Glick SD α3β4 nicotinic acetylcholine receptors in the medial habenula modulate the mesolimbic dopaminergic response to acute nicotine in vivo. Neuropharmacology 2012, 63, 434–440. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 134.Jackson KJ; Sanjakdar SS; Muldoon PP; McIntosh JM; Damaj MI The α3β4 nicotinic acetylcholine receptor subtype mediates nicotine reward and physical nicotine withdrawal signs independently of the α5 subunit in the mouse. Neuropharmacology 2013, 70, 228–235. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 135.Glick SD; Sell EM; McCallum SE; Maisonneuve IM Brain regions mediating α3β4 nicotinic antagonist effects of 18-MC on nicotine self-administration. European Journal of Pharmacology 2011, 669, 71–75. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 136.Li X; You S; Xiong J; Qiao Y; Yu J; Zhangsun D; Luo S α-Conotoxin TxID and [S9K]TxID, α3β4 nAChR Antagonists, Attenuate Expression and Reinstatement of Nicotine-Induced Conditioned Place Preference in Mice. Marine Drugs 2020, 18. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 137.Elayouby KS; Ishikawa M; Dukes AJ; Smith ACW; Lu Q; Fowler CD; Kenny PJ α3 Nicotinic Acetylcholine Receptors in the Habenula-Interpeduncular Nucleus Circuit Regulate Nicotine Intake. The Journal of Neuroscience 2021, 41, 1779–1787. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 138.Muldoon PP; Jackson KJ; Perez E; Harenza JL; Molas S; Rais B; Anwar H; Zaveri NT; Maldonado R; Maskos U; McIntosh JM; Dierssen M; Miles MF; Chen X; De Biasi M; Damaj MI The α3β4 nicotinic ACh receptor subtype mediates physical dependence to morphine: mouse and human studies. British Journal of Pharmacology 2014, 171, 3845–3857. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 139.Glick SD; Ramirez RL; Livi JM; Maisonneuve IM 18-Methoxycoronaridine acts in the medial habenula and/or interpeduncular nucleus to decrease morphine self-administration in rats. European Journal of Pharmacology 2006, 537, 94–98. [DOI] [PubMed] [Google Scholar]
- 140.Donvito G; Muldoon PP; Jackson KJ; Ahmad U; Zaveri NT; McIntosh JM; Chen X; Lichtman AH; Damaj MI Neuronal nicotinic acetylcholine receptors mediate Δ9-THC dependence: Mouse and human studies. Addict Biol 2020, 25, e12691. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 141.Gehrmann J; Alewood PF; Craik DJ Structure determination of the three disulfide bond isomers of α-conotoxin GI: a model for the role of disulfide bonds in structural stability. Journal of molecular biology 1998, 278, 401–415. [DOI] [PubMed] [Google Scholar]
- 142.Muttenthaler M; Nevin ST; Grishin AA; Ngo ST; Choy PT; Daly NL; Hu S; Armishaw CJ; Wang CA; Lewis RJ; Martin JL; Noakes PG; Craik DJ; Adams DJ; Alewood PF Solving the α-Conotoxin Folding Problem: Efficient Selenium-Directed On-Resin Generation of More Potent and Stable Nicotinic Acetylcholine Receptor Antagonists. Journal of the American Chemical Society 2010, 132, 3514–3522. [DOI] [PubMed] [Google Scholar]
- 143.Astraea Therapeutics. Empowering patients fighting substance abuse. https://www.astraeatherapeutics.com (accessed August 17, 2022).
- 144.Zaveri N; Jiang F; Olsen C; Polgar W; Toll L Novel α3β4 Nicotinic Acetylcholine Receptor-Selective Ligands. Discovery, Structure–Activity Studies, and Pharmacological Evaluation. J. Med. Chem 2010, 53, 8187–8191. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 145.Toll L; Zaveri NT; Polgar WE; Jiang Faming; Khroyan TV; Zhou Wei; Xie X; Stauber GB; Costello MR; Leslie FM AT-1001: A High Affinity and Selective α3β4 Nicotinic Acetylcholine Receptor Antagonist Blocks Nicotine Self-Administration in Rats. Neuropsychopharmacology (New York, N.Y.) 2012, 37, 1367–1376. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 146.Wu J; Perry DC; Bupp JE; Jiang F; Polgar WE; Toll L; Zaveri NT [125I]AT-1012, a new high affinity radioligand for the α3β4 nicotinic acetylcholine receptors. Neuropharmacology 2014, 77, 193–199. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 147.Cippitelli A; Wu J; Gaiolini KA; Mercatelli D; Schoch J; Gorman M; Ramirez A; Ciccocioppo R; Khroyan TV; Yasuda D; Zaveri NT; Pascual C; Xie X; Toll L AT-1001: a high-affinity α3β4 nAChR ligand with novel nicotine-suppressive pharmacology. British Journal of Pharmacology 2015, 172, 1834–1845. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 148.Knox HJ; Rego Campello H; Lester HA; Gallagher T; Dougherty DA Characterization of Binding Site Interactions and Selectivity Principles in the α3β4 Nicotinic Acetylcholine Receptor. J. Am. Chem. Soc 2022, 144, 16101–16117. [DOI] [PubMed] [Google Scholar]
- 149.Yuan M; Malagon AM; Yasuda D; Belluzzi JD; Leslie FM; Zaveri NT The α3β4 nAChR partial agonist AT-1001 attenuates stress-induced reinstatement of nicotine seeking in a rat model of relapse and induces minimal withdrawal in dependent rats. Behavioural Brain Research 2017, 333, 251–257. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 150.Cippitelli A; Brunori G; Gaiolini KA; Zaveri NT; Toll L Pharmacological stress is required for the anti-alcohol effect of the α3β4* nAChR partial agonist AT-1001. Neuropharmacology 2015, 93, 229–236. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 151.Coe JW; Vetelino MG; Bashore CG; Wirtz MC; Brooks PR; Arnold EP; Lebel LA; Fox CB; Sands SB; Davis TI; Schulz DW; Rollema H; Tingley FD; O'Neill BT In pursuit of α4β2 nicotinic receptor partial agonists for smoking cessation: Carbon analogs of (−)-cytisine. Bioorganic & Medicinal Chemistry Letters 2005, 15, 2974–2979. [DOI] [PubMed] [Google Scholar]
- 152.Coe JW; Brooks PR; Wirtz MC; Bashore CG; Bianco KE; Vetelino MG; Arnold EP; Lebel LA; Fox CB; Tingley FD; Schulz DW; Davis TI; Sands SB; Mansbach RS; Rollema H; O’Neill BT 3,5-Bicyclic aryl piperidines: A novel class of α4β2 neuronal nicotinic receptor partial agonists for smoking cessation. Bioorganic & Medicinal Chemistry Letters 2005, 15, 4889–4897. [DOI] [PubMed] [Google Scholar]
- 153.Lowe JA; DeNinno SL; Coe JW; Zhang L; Mente S; Hurst RS; Mather RJ; Ward KM; Shrikhande A; Rollema H; Johnson DE; Horner W; Gorczyca R; Tingley FD; Kozak R; Majchrzak MJ; Tritto T; Sadlier J; Shaffer CL; Ellerbrock B; Osgood SM; MacDougall MC; McDowell LL A novel series of [3.2.1] azabicyclic biaryl ethers as α3β4 and α6/4β4 nicotinic receptor agonists. Bioorganic & Medicinal Chemistry Letters 2010, 20, 4749–4752. [DOI] [PubMed] [Google Scholar]
- 154.Zaveri NT; Jiang F US 9,062,042 B2, 2015.
- 155.Chatterjee S; Steensland P; Simms JA; Holgate J; Coe JW; Hurst RS; Shaffer CL; Lowe J; Rollema H; Bartlett SE Partial Agonists of the α3β4 Neuronal Nicotinic Acetylcholine Receptor Reduce Ethanol Consumption and Seeking in Rats. Neuropsychopharmacology 2011, 36, 603–615. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 156.Sałaga M; Kowalczuk A; Zielinska M; Błażewicz A; Fichna J Calea zacatechichi dichloromethane extract exhibits antidiarrheal and antinociceptive effects in mouse models mimicking irritable bowel syndrome. Naunyn Schmiedebergs Arch. Pharmacol 2015, 388, 1069–1077. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 157.Argade MD; Straub CJ; Rusali LE; Santarsiero BD; Riley AP Synthesis of Aristoquinoline Enantiomers and Their Evaluation at the α3β4 Nicotinic Acetylcholine Receptor. Org. Lett 2021, 23, 7693–7697. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 158.Arias HR; Ortells MO; Feuerbach D; Burgos V; Paz C Alkaloids Purified from Aristotelia chilensis Inhibit the Human α3β4 Nicotinic Acetylcholine Receptor with Higher Potencies Compared with the Human α4β2 and α7 Subtypes. J. Nat. Prod 2019, 82, 1953–1960. [DOI] [PubMed] [Google Scholar]
- 159.Richards DP; Patel RN; Duce IR; Khambay BPS; Birkett MA; Pickett JA; Mellor IR (−)-Adaline from the Adalia Genus of Ladybirds Is a Potent Antagonist of Insect and Specific Mammalian Nicotinic Acetylcholine Receptors. Molecules (Basel, Switzerland) 2022, 27, 7074. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 160.Kachel HS; Patel RN; Franzyk H; Mellor IR Block of nicotinic acetylcholine receptors by philanthotoxins is strongly dependent on their subunit composition. Scientific Reports 2016, 6, 38116. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 161.Crummy EA; O’Neal TJ; Baskin BM; Ferguson SM One Is Not Enough: Understanding and Modeling Polysubstance Use. Front. Neurosci 2020, 14, 569. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 162.Pearl SM; Hough LB; Boyd DL; Glick SD Sex Differences in Ibogaine Antagonism of Morphine-induced Locomotor Activity and in Ibogaine Brain Levels and Metabolism. Pharmacology Biochemistry and Behavior 1997, 57, 809–815. [DOI] [PubMed] [Google Scholar]
- 163.Kuehne ME; He L; Jokiel PA; Pace CJ; Fleck MW; Maisonneuve IM; Glick SD; Bidlack JM Synthesis and biological evaluation of 18-methoxycoronaridine congeners. Potential antiaddiction agents. J. Med. Chem 2003, 46, 2716–2730. [DOI] [PubMed] [Google Scholar]
- 164.Deecher DC; Teitler M; Soderlund DM; Bornmann WG; Kuehne ME; Glick SD Mechanisms of action of ibogaine and harmaline congeners based on radioligand binding studies. Brain Res. 1992, 571, 242–247. [DOI] [PubMed] [Google Scholar]
- 165.Sheffield EB; Quick MW; Lester RAJ Nicotinic acetylcholine receptor subunit mRNA expression and channel function in medial habenula neurons. Neuropharmacology 2000, 39, 2591–2603. [DOI] [PubMed] [Google Scholar]


